RE: Last dip7 Jan 2020 13:16
Comment on the web this am
So for use of proceeds, should we scrap the stated reasons as follows:
The net proceeds of the Placing will be used to analyse the Phase I/II clinical trial of VAL201 to treat prostate cancer and associated metastatic conditions and continue the development of ValiRx's pre-clinical VAL301 and VAL101/GeneICE programmes towards the clinic, and for general working capital purposes.
And just replace it with:
The net proceeds of the Placing will be used to cover the costs of effecting a capital reorganisation so that our long suffering shareholders can be further fleeced as the company tries to raise yet more capital to waste on corporate hangers on and crony capitalists?